Person · CIK 1376099

Jack Kaye

Director at uniQure and Dyadic International

Earlier: Keryx Biopharmaceuticals

Source: Forms 3, 4, 5 and 144 on SEC EDGAR

Sold on Form 4$3.2M
Noticed on Form 144$2.8M
Bought on Form 4$15K
Companies3

Holdings now

As reported after the latest Form 3, 4 or 5 at each company.

How these figures work

Options and RSUs are from the latest filing that lists them; earlier grants may also be held. Holdings can be out of date when a person stops filing.

CompanySecurityHeldShares or unitsAs of
uniQure QUREOrdinary SharesDirectly25,996Jun 30, 2026 · Filing · EDGAR
Dyadic International DYAICommon StockDirectly81,201Jan 2, 2026 · Filing · EDGAR
Dyadic International DYAIStock Option
exercise $0.94, expires Jan 2, 2036, into Common Stock
Directly67,500Jan 2, 2026 · Filing · EDGAR
Dyadic International DYAIRestricted Stock Unit
into Common Stock
Directly39,894Jan 2, 2026 · Filing · EDGAR
Keryx BiopharmaceuticalsCommon StockDirectly85,000Jun 17, 2015 · Filing · EDGAR
Keryx BiopharmaceuticalsCommon StockOwned by Spouse1,400Jun 19, 2007 · Filing · EDGAR

Sold and noticed by quarter

Jack Kaye: dollars sold on Form 4 and noticed on Form 144 per quarter, Q1 2021 to Q4 2026$1.3M$0Q1 2021: notice not machine-readableQ1 2021: $19K sold on Form 4Q2 2021: $0 noticed on Form 144Q2 2021: $0 sold on Form 4Q3 2021: $0 noticed on Form 144Q3 2021: $0 sold on Form 4Q4 2021: $0 noticed on Form 144Q4 2021: $0 sold on Form 4Q1 2022: notice not machine-readableQ1 2022: $10K sold on Form 4Q2 2022: $0 noticed on Form 144Q2 2022: $0 sold on Form 4Q3 2022: $0 noticed on Form 144Q3 2022: $0 sold on Form 4Q4 2022: $0 noticed on Form 144Q4 2022: $0 sold on Form 4Q1 2023: notice not machine-readableQ1 2023: $8K sold on Form 4Q2 2023: $0 noticed on Form 144Q2 2023: $43K sold on Form 4Q3 2023: $0 noticed on Form 144Q3 2023: $0 sold on Form 4Q4 2023: $0 noticed on Form 144Q4 2023: $0 sold on Form 4Q1 2024: $0 noticed on Form 144Q1 2024: $0 sold on Form 4Q2 2024: $0 noticed on Form 144Q2 2024: $11K sold on Form 4Q3 2024: $0 noticed on Form 144Q3 2024: $0 sold on Form 4Q4 2024: $0 noticed on Form 144Q4 2024: $0 sold on Form 4Q1 2025: $0 noticed on Form 144Q1 2025: $0 sold on Form 4Q2 2025: $0 noticed on Form 144Q2 2025: $31K sold on Form 4Q3 2025: $0 noticed on Form 144Q3 2025: $0 sold on Form 4Q4 2025: $1.3M noticed on Form 144Q4 2025: $1.2M sold on Form 4Q1 2026: $174K noticed on Form 144Q1 2026: $174K sold on Form 4Q2 2026: $1.3M noticed on Form 144Q2 2026: $1.3M sold on Form 4Q3 2026: $0 noticed on Form 144Q3 2026: $0 sold on Form 4Q4 2026: $0 noticed on Form 144Q4 2026: $0 sold on Form 4Q1 2021Q2 2022Q3 2023Q4 2024Q1 2026

Sold (Form 4) Noticed (Form 144) Bought (Form 4)

Quarterly totals as a table
QuarterSold (Form 4)Noticed (Form 144)Bought (Form 4)
Q2 2026$1.3M$1.3M—
Q1 2026$174K$174K—
Q4 2025$1.2M$1.3M—
Q2 2025$31K——
Q2 2024$11K——
Q2 2023$43K——
Q1 2023$8KNot machine-readable—
Q1 2022$10KNot machine-readable—
Q1 2021$19KNot machine-readable—
Q1 2020$50KNot machine-readable—
Q1 2019$38KNot machine-readable—
Q1 2018$53KNot machine-readable—
Q4 2010$100KNot machine-readable—
Q3 2010$125KNot machine-readable—
Q2 2007——$15K

Form 144 notices went onto EDGAR as structured data on April 13, 2023. Earlier notices were filed on paper and cannot be read here, so those quarters show no noticed amount.

Planned sales (Form 144) and the sales that followed

Each Form 144 notice of a planned sale, grouped by broker and 10b5-1 plan, with the Form 4 sales we matched to it.

How we match

A Form 144 is a notice of a planned sale by an affiliate. SEC Tracker matches each notice to Form 4 sales by the same person at the same company within 90 days of the notice, up to the shares noticed. The match is our inference, not something either filing states.

Notice dateNoticedPlanned saleOutcomeLinks
uniQure QURE · Citigroup Global Markets · 10b5-1 plan adopted Jun 16, 2025 · 5 notices
Jun 30, 202621,167 · ~$983KJun 30, 2026Sold as noticed Sold 21,167 in 2 sales, Jun 30 to Jun 30 · $983K Form 4Filing · EDGAR
Jun 17, 20265,295 · ~$225KJun 17, 2026Sold as noticed Sold 5,295 at $42.57 on Jun 17 · $225K Form 4Filing · EDGAR
Jun 3, 20262,645 · ~$79KJun 3, 2026Sold as noticed Sold 2,645 at $30.01 on Jun 3 · $79K Form 4Filing · EDGAR
Jan 9, 20266,390 · ~$174KJan 9, 2026Sold as noticed Sold 6,390 at $27.28 on Jan 9 · $174K Form 4Filing · EDGAR
Nov 4, 202538,810 · ~$1.3MNov 4, 2025Sold as noticed Sold 38,810 in 3 sales, Nov 4 to Nov 4 · $1.2M Form 4Filing · EDGAR
uniQure QURE · Citigroup Global Markets · No 10b5-1 plan stated · 1 notice
Jun 11, 20261,993 · ~$54KJun 11, 2026Sold as noticed Sold 1,993 at $27.06 on Jun 11 · $54K Form 4Filing · EDGAR
Sales without a matching Form 144 · 11 sales
No matching Form 144 found. Not every sale needs one: small sales and sales by people who are not affiliates are exempt.
———Sold without notice uniQure (QURE): Sold 2,112 at $14.45 on Jun 20, 2025 · $31KFiling · EDGAR
———Sold without notice uniQure (QURE): Sold 2,218 at $5.16 on Jun 13, 2024 · $11KFiling · EDGAR
———Sold without notice uniQure (QURE): Sold 2,280 at $18.93 on Jun 16, 2023 · $43KFiling · EDGAR
———Notice not machine-readable uniQure (QURE): Sold 384 at $19.99 on Feb 27, 2023 · $8KFiling · EDGAR
———Notice not machine-readable uniQure (QURE): Sold 600 at $16.76 on Feb 28, 2022 · $10KFiling · EDGAR
———Notice not machine-readable uniQure (QURE): Sold 504 at $37.60 on Mar 2, 2021 · $19KFiling · EDGAR
———Notice not machine-readable uniQure (QURE): Sold 806 at $62.20 on Jan 28, 2020 · $50KFiling · EDGAR
———Notice not machine-readable uniQure (QURE): Sold 1,210 at $31.31 on Jan 28, 2019 · $38KFiling · EDGAR
———Notice not machine-readable uniQure (QURE): Sold 2,878 at $18.53 on Jan 29, 2018 · $53KFiling · EDGAR
———Notice not machine-readable Keryx Biopharmaceuticals: Sold 20,000 at $5.00 on Dec 6, 2010 · $100KFiling · EDGAR
———Notice not machine-readable Keryx Biopharmaceuticals: Sold 25,000 at $5.02 on Sep 29, 2010 · $125KFiling · EDGAR

Every transaction, by company

Each Form 3, 4 and 5 transaction in plain words, newest first.

How these figures work

Values are shares times the price each filing states; grants, exercises and gifts usually state no price. Held after is what the filing reports was held once the transaction was done, directly or through the named holder.

uniQure QURE Director · filings 2017 to 2026 · sold $3M · $2.8M noticed on Form 144

DateTransactionSharesPriceValueHeld afterSource
Jun 30, 2026Option or RSU exercised or converted+4,107$37.00$152K30,103 directFiling · EDGAR
Jun 30, 2026Sale under a 10b5-1 plan−4,107$46.49$191K25,996 directFiling · EDGAR
Jun 30, 2026Option or RSU exercised or converted+17,060$20.18$344K43,056 directFiling · EDGAR
Jun 30, 2026Sale under a 10b5-1 plan−17,060$46.43$792K25,996 directFiling · EDGAR
Jun 30, 2026Option or RSU exercised or converted
Stock Option (Right to Buy)
−4,1070 directFiling · EDGAR
Jun 30, 2026Option or RSU exercised or converted
Stock Option (Right to Buy)
−17,0600 directFiling · EDGAR
Jun 17, 2026Option or RSU exercised or converted+5,295$31.71$168K31,291 directFiling · EDGAR
Jun 17, 2026Sale under a 10b5-1 plan−5,295$42.57$225K25,996 directFiling · EDGAR
Jun 17, 2026Option or RSU exercised or converted
Stock Option (Right to Buy)
−5,2950 directFiling · EDGAR
Jun 11, 2026Open-market or private sale−1,993$27.06$54K25,996 directFiling · EDGAR
Jun 10, 2026Grant or award from the company+7,55027,989 directFiling · EDGAR
Jun 10, 2026Grant or award from the company
Stock Option (Right to Buy)
+13,98013,980 directFiling · EDGAR
Jun 3, 2026Option or RSU exercised or converted+2,645$16.04$42K23,084 directFiling · EDGAR
Jun 3, 2026Sale under a 10b5-1 plan−2,645$30.01$79K20,439 directFiling · EDGAR
Jun 3, 2026Option or RSU exercised or converted
Stock Option (Right to Buy)
−2,6450 directFiling · EDGAR
Jan 9, 2026Option or RSU exercised or converted+6,390$19.39$124K26,829 directFiling · EDGAR
Jan 9, 2026Sale under a 10b5-1 plan−6,390$27.28$174K20,439 directFiling · EDGAR
Jan 9, 2026Option or RSU exercised or converted
Stock Option (Right to Buy)
−6,3900 directFiling · EDGAR
Nov 4, 2025Option or RSU exercised or converted+10,000$7.37$74K30,439 directFiling · EDGAR
Nov 4, 2025Sale under a 10b5-1 plan−10,000$30.36$304K20,439 directFiling · EDGAR
Nov 4, 2025Option or RSU exercised or converted+11,000$5.37$59K31,439 directFiling · EDGAR
Nov 4, 2025Sale under a 10b5-1 plan−11,000$30.34$334K20,439 directFiling · EDGAR
Nov 4, 2025Option or RSU exercised or converted+17,810$14.08$251K38,249 directFiling · EDGAR
Nov 4, 2025Sale under a 10b5-1 plan−17,810$30.33$540K20,439 directFiling · EDGAR
Nov 4, 2025Option or RSU exercised or converted
Stock Option (Right to Buy)
−10,0000 directFiling · EDGAR
Nov 4, 2025Option or RSU exercised or converted
Stock Option (Right to Buy)
−11,0000 directFiling · EDGAR
Nov 4, 2025Option or RSU exercised or converted
Stock Option (Right to Buy)
−17,8100 directFiling · EDGAR
Jun 20, 2025Open-market or private sale−2,112$14.45$31K20,439 directFiling · EDGAR
Jun 11, 2025Grant or award from the company+7,97022,551 directFiling · EDGAR
Jun 11, 2025Grant or award from the company
Stock Option (Right to Buy)
+15,63015,630 directFiling · EDGAR
Jun 19, 2024Grant or award from the company+8,08014,581 directFiling · EDGAR
Jun 19, 2024Grant or award from the company
Stock Option (Right to Buy)
+15,84015,840 directFiling · EDGAR
Jun 13, 2024Open-market or private sale−2,218$5.16$11K6,501 directFiling · EDGAR
Jun 23, 2023Gift−12,70021,419 directFiling · EDGAR
Jun 23, 2023Gift−12,7008,719 directFiling · EDGAR
Jun 16, 2023Open-market or private sale−2,280$18.93$43K34,119 directFiling · EDGAR
Jun 13, 2023Grant or award from the company+8,70036,399 directFiling · EDGAR
Jun 13, 2023Grant or award from the company
Stock Option (Right to Buy)
+17,06017,060 directFiling · EDGAR
Feb 27, 2023Open-market or private sale−384$19.99$8K27,699 directFiling · EDGAR
Jun 15, 2022Grant or award from the company+9,08028,083 directFiling · EDGAR
Jun 15, 2022Grant or award from the company
Stock Option (Right to Buy)
+17,81017,810 directFiling · EDGAR
Feb 28, 2022Open-market or private sale−600$16.76$10K19,003 directFiling · EDGAR
Feb 24, 2022Grant or award from the company+1,53419,603 directFiling · EDGAR
Feb 24, 2022Grant or award from the company
Stock Option (Right to Buy)
+2,6452,645 directFiling · EDGAR
Mar 2, 2021Open-market or private sale−504$37.60$19K18,069 directFiling · EDGAR
Feb 25, 2021Grant or award from the company+2,38218,573 directFiling · EDGAR
Feb 25, 2021Grant or award from the company
Stock Option (Right to Buy)
+4,1074,107 directFiling · EDGAR
Feb 27, 2020Grant or award from the company+2,06316,191 directFiling · EDGAR
Feb 27, 2020Grant or award from the company
Stock Option (Right to Buy)
+3,6203,620 directFiling · EDGAR
Jan 28, 2020Open-market or private sale−806$62.20$50K14,128 directFiling · EDGAR
Jan 28, 2019Open-market or private sale−1,210$31.31$38K14,934 directFiling · EDGAR
Jan 25, 2019Grant or award from the company+3,23016,144 directFiling · EDGAR
Jan 25, 2019Grant or award from the company
Stock Option (Right to Buy)
+5,2955,295 directFiling · EDGAR
Jan 29, 2018Open-market or private sale−2,878$18.53$53K12,914 directFiling · EDGAR
Jan 26, 2018Grant or award from the company+4,79215,792 directFiling · EDGAR
Jan 26, 2018Grant or award from the company
Stock Option (Right to Buy)
+6,3906,390 directFiling · EDGAR
Jan 27, 2017Grant or award from the company
Stock Option (Right to Buy)
+11,00011,000 directFiling · EDGAR
Jan 27, 2017Grant or award from the company
Restricted Stock Units
+11,00011,000 directFiling · EDGAR

Dyadic International DYAI Director · filings 2019 to 2026

DateTransactionSharesPriceValueHeld afterSource
Jan 2, 2026Option or RSU exercised or converted+21,55281,201 directFiling · EDGAR
Jan 2, 2026Option or RSU exercised or converted
Restricted Stock Unit
−21,5520 directFiling · EDGAR
Jan 2, 2026Grant or award from the company
Stock Option
+67,50067,500 directFiling · EDGAR
Jan 2, 2026Grant or award from the company
Restricted Stock Unit
+39,89439,894 directFiling · EDGAR
Mar 5, 2025Option or RSU exercised or converted+7,500$1.33$10K64,666 directFiling · EDGAR
Mar 5, 2025Option or RSU exercised or converted+22,500$1.33$30K87,166 directFiling · EDGAR
Mar 5, 2025Shares withheld for tax or exercise price−27,517$1.45$40K59,649 directFiling · EDGAR
Mar 5, 2025Option or RSU exercised or converted
Stock Option
−7,5000 directFiling · EDGAR
Mar 5, 2025Option or RSU exercised or converted
Stock Option
−22,5000 directFiling · EDGAR
Jan 2, 2025Option or RSU exercised or converted+23,58557,166 directFiling · EDGAR
Jan 2, 2025Option or RSU exercised or converted
Restricted Stock Unit
−23,5850 directFiling · EDGAR
Jan 2, 2025Grant or award from the company
Stock Option
+67,50067,500 directFiling · EDGAR
Jan 2, 2025Grant or award from the company
Restricted Stock Unit
+21,55221,552 directFiling · EDGAR
Jan 3, 2024Option or RSU exercised or converted+27,17433,581 directFiling · EDGAR
Jan 3, 2024Option or RSU exercised or converted
Restricted Stock Unit
−27,1740 directFiling · EDGAR
Jan 2, 2024Grant or award from the company
Stock Option
+67,50067,500 directFiling · EDGAR
Jan 2, 2024Grant or award from the company
Restricted Stock Unit
+23,58523,585 directFiling · EDGAR
Jan 3, 2023Grant or award from the company
Stock Option
+52,50052,500 directFiling · EDGAR
Jan 3, 2023Grant or award from the company
Restricted Stock Unit
+27,17427,174 directFiling · EDGAR
Nov 21, 2022Gift−33,15039,557 directFiling · EDGAR
Nov 21, 2022Gift−33,1506,407 directFiling · EDGAR
Jun 10, 2022Grant or award from the company
Stock Option
+25,00025,000 directFiling · EDGAR
Jan 3, 2022Grant or award from the company
Stock Option
+52,50052,500 directFiling · EDGAR
Jan 4, 2021Grant or award from the company
Stock Option
+52,50052,500 directFiling · EDGAR
Jan 2, 2020Grant or award from the company
Stock Option
+75,00075,000 directFiling · EDGAR
Jun 25, 2019Grant or award from the company
Stock Option
+25,00025,000 directFiling · EDGAR

Keryx Biopharmaceuticals Director · filings 2006 to 2015 · sold $226K · bought $15K

DateTransactionSharesPriceValueHeld afterSource
Jun 17, 2015Grant or award from the company+10,00085,000 directFiling · EDGAR
Jun 17, 2015Grant or award from the company
Stock Options (right to buy)
+30,00030,000 directFiling · EDGAR
Jun 24, 2014Grant or award from the company+10,00075,000 directFiling · EDGAR
Jun 24, 2014Grant or award from the company
Stock Options (right to buy)
+30,00030,000 directFiling · EDGAR
Sep 6, 2013Gift−6,000$9.13$55K74,000 directFiling · EDGAR
Sep 6, 2013Gift−3,000$9.13$27K71,000 directFiling · EDGAR
Sep 6, 2013Gift−6,000$9.13$55K65,000 directFiling · EDGAR
Jun 19, 2013Grant or award from the company+15,00080,000 directFiling · EDGAR
Jun 19, 2013Grant or award from the company
Stock Options (right to buy)
+25,00025,000 directFiling · EDGAR
Jun 27, 2012Gift−5,000$1.81$9K70,000 directFiling · EDGAR
Jun 27, 2012Gift−5,000$1.81$9K65,000 directFiling · EDGAR
Jun 20, 2012Grant or award from the company+15,00075,000 directFiling · EDGAR
Jun 20, 2012Grant or award from the company
Stock Options (right to buy)
+25,00025,000 directFiling · EDGAR
Jan 3, 2012Gift−9,720$2.65$26K60,000 directFiling · EDGAR
Dec 15, 2011Gift−86,680$2.42$210K69,720 directFiling · EDGAR
Jun 22, 2011Grant or award from the company+15,000156,400 directFiling · EDGAR
Jun 22, 2011Grant or award from the company
Stock Options (Right to Buy)
+25,00025,000 directFiling · EDGAR
Dec 6, 2010Open-market or private sale−20,000$5.00$100K141,400 directFiling · EDGAR
Sep 29, 2010Open-market or private sale−25,000$5.02$125K161,400 directFiling · EDGAR
Jun 16, 2010Grant or award from the company+15,000186,400 directFiling · EDGAR
Jun 16, 2010Grant or award from the company
Stock Options (Right to buy)
+25,00025,000 directFiling · EDGAR
Sep 19, 2009Grant or award from the company
Stock Options (Right to Buy)
+30,00030,000 directFiling · EDGAR
Jun 17, 2009Grant or award from the company
Stock Options (Right to Buy)
+10,00010,000 directFiling · EDGAR
Jun 16, 2009Grant or award from the company+75,000171,400 directFiling · EDGAR
May 22, 2009Open-market or private purchase+35,00096,400 directFiling · EDGAR
Nov 14, 2008Grant or award from the company+60,00061,400 directFiling · EDGAR
Jun 18, 2008Grant or award from the company
Stock Options (Right to Buy)
+10,00010,000 directFiling · EDGAR
Jun 21, 2007Grant or award from the company
Stock Options (Right to Buy)
+10,00010,000 directFiling · EDGAR
Jun 19, 2007Open-market or private purchase+1,400$10.50$15K1,400
Owned by Spouse
Filing · EDGAR
All 63 Forms 3, 4, 5 and 144
FiledFormCompanyLinks
Jul 2, 2026Form 4uniQure QUREFiling · EDGAR
Jun 30, 2026Form 144uniQure QUREFiling · EDGAR
Jun 22, 2026Form 4uniQure QUREFiling · EDGAR
Jun 17, 2026Form 144uniQure QUREFiling · EDGAR
Jun 12, 2026Form 4uniQure QUREFiling · EDGAR
Jun 11, 2026Form 144uniQure QUREFiling · EDGAR
Jun 5, 2026Form 4uniQure QUREFiling · EDGAR
Jun 3, 2026Form 144uniQure QUREFiling · EDGAR
Jan 12, 2026Form 4uniQure QUREFiling · EDGAR
Jan 9, 2026Form 144uniQure QUREFiling · EDGAR
Jan 6, 2026Form 4Dyadic International DYAIFiling · EDGAR
Nov 6, 2025Form 4uniQure QUREFiling · EDGAR
Nov 4, 2025Form 144uniQure QUREFiling · EDGAR
Jun 24, 2025Form 4uniQure QUREFiling · EDGAR
Jun 13, 2025Form 4uniQure QUREFiling · EDGAR
Mar 7, 2025Form 4Dyadic International DYAIFiling · EDGAR
Jan 7, 2025Form 4Dyadic International DYAIFiling · EDGAR
Jun 21, 2024Form 4uniQure QUREFiling · EDGAR
Jun 17, 2024Form 4uniQure QUREFiling · EDGAR
Feb 6, 2024Form 5uniQure QUREFiling · EDGAR
Jan 4, 2024Form 4Dyadic International DYAIFiling · EDGAR
Jun 20, 2023Form 4uniQure QUREFiling · EDGAR
Mar 1, 2023Form 4uniQure QUREFiling · EDGAR
Jan 5, 2023Form 5Dyadic International DYAIFiling · EDGAR
Jan 5, 2023Form 4Dyadic International DYAIFiling · EDGAR
Jun 17, 2022Form 4uniQure QUREFiling · EDGAR
Jun 14, 2022Form 4Dyadic International DYAIFiling · EDGAR
Mar 2, 2022Form 4uniQure QUREFiling · EDGAR
Feb 28, 2022Form 4uniQure QUREFiling · EDGAR
Jan 5, 2022Form 4Dyadic International DYAIFiling · EDGAR
Mar 4, 2021Form 4uniQure QUREFiling · EDGAR
Mar 1, 2021Form 4uniQure QUREFiling · EDGAR
Jan 6, 2021Form 4Dyadic International DYAIFiling · EDGAR
Mar 2, 2020Form 4uniQure QUREFiling · EDGAR
Jan 30, 2020Form 4uniQure QUREFiling · EDGAR
Jan 3, 2020Form 4Dyadic International DYAIFiling · EDGAR
Jun 27, 2019Form 4Dyadic International DYAIFiling · EDGAR
Feb 13, 2019Form 3Dyadic International DYAIFiling · EDGAR
Jan 31, 2019Form 4uniQure QUREFiling · EDGAR
Jan 31, 2019Form 4uniQure QUREFiling · EDGAR
Jan 31, 2018Form 4uniQure QUREFiling · EDGAR
Jan 30, 2018Form 4uniQure QUREFiling · EDGAR
Jan 31, 2017Form 4uniQure QUREFiling · EDGAR
Jan 10, 2017Form 3uniQure QUREFiling · EDGAR
Jun 18, 2015Form 4Keryx BiopharmaceuticalsFiling · EDGAR
Jun 26, 2014Form 4Keryx BiopharmaceuticalsFiling · EDGAR
Sep 9, 2013Form 4Keryx BiopharmaceuticalsFiling · EDGAR
Jun 21, 2013Form 4Keryx BiopharmaceuticalsFiling · EDGAR
Feb 15, 2013Form 4Keryx BiopharmaceuticalsFiling · EDGAR
Jun 22, 2012Form 4Keryx BiopharmaceuticalsFiling · EDGAR
Jan 4, 2012Form 4Keryx BiopharmaceuticalsFiling · EDGAR
Dec 19, 2011Form 4Keryx BiopharmaceuticalsFiling · EDGAR
Jul 13, 2011Form 4Keryx BiopharmaceuticalsFiling · EDGAR
Dec 8, 2010Form 4Keryx BiopharmaceuticalsFiling · EDGAR
Oct 1, 2010Form 4Keryx BiopharmaceuticalsFiling · EDGAR
Jun 18, 2010Form 4Keryx BiopharmaceuticalsFiling · EDGAR
Sep 22, 2009Form 4Keryx BiopharmaceuticalsFiling · EDGAR
Jun 18, 2009Form 4Keryx BiopharmaceuticalsFiling · EDGAR
May 22, 2009Form 4Keryx BiopharmaceuticalsFiling · EDGAR
Nov 18, 2008Form 4Keryx BiopharmaceuticalsFiling · EDGAR
Jun 20, 2008Form 4Keryx BiopharmaceuticalsFiling · EDGAR
Jun 22, 2007Form 4Keryx BiopharmaceuticalsFiling · EDGAR
Sep 22, 2006Form 3Keryx BiopharmaceuticalsFiling · EDGAR

Every figure is as filed with the SEC on Forms 3, 4, 5 and 144. Holdings are the amounts reported after each person's latest filing at each company and can be out of date. Matching a Form 144 notice to Form 4 sales is SEC Tracker's inference from owner, company, dates and share counts, not something the filings state. Not investment advice. Not affiliated with the U.S. SEC.

Data on this page was fetched . The filing on SEC.gov is the record.